BARDA Archives - EverGlade Consulting

BARDA

immunoassay IEID Lab Solicitation

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats

Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure. BARDA’s RRPV initiative calls for laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays […]

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats Read More »

BARDA merge with ARPA-H

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures

The U.S. Department of Health and Human Services (HHS) is undergoing one of the most significant structural transformations in its history. This realignment affects not only public health preparedness and biomedical innovation but also the broader operational framework, including funding mechanisms, programmatic leadership, and cross-agency coordination structures that supports millions of Americans across health care,

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures Read More »

antiviral therapeutics against filoviruses

New Opportunities with DRIVe: ReBooT and RePAIR Amendments

Amendment 034 – DRIVe EZ BAA_ReBooT_RePAIR New Opportunities with DRIVe: ReBooT and RePAIR Amendments The Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation & Ventures (DRIVe) has announced updates to its Easy Broad Agency Announcement (EZ-BAA) with Amendment #034. This amendment reopens and revises the ReBooT (AOI #22) program and pauses the

New Opportunities with DRIVe: ReBooT and RePAIR Amendments Read More »

PAHPA program funding

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness

Congress’s passage of a continuing resolution (CR) has averted a shutdown and provided temporary relief until late March. However, this short-term fix exposes significant gaps in public health and technology preparedness that demand immediate attention. As critical programs approach expiration and threats beyond the Pandemic and All-Hazards Preparedness Act (PAHPA) remain unresolved, lawmakers have a

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness Read More »

drug-resistant bacterial infections

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

PBS+AMR+2025+SSN+-+Final The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens Read More »

Marburg virus (MARV) and Sudan virus (SUDV) vaccines clinical trials

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines

SSN_MARV__SUDV_Vaccines Purpose The Biomedical Advanced Research and Development Authority (BARDA), under the Administration for Strategic Preparedness and Response (ASPR) has issued a Sources Sought Notice (SSN). The subject of this SSN is Marburg virus (MARV) and Sudan virus (SUDV) vaccines in active or completed Phase 2 clinical trials. Insights on current and prospective MARV and

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines Read More »

monoclonal antibody

BARDA Announces Solicitation to Improve Monoclonal Antibody Platforms for Pre-Exposure Prophylaxis

PrEP_Solicitation_Monoclonal_Antibody_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of monoclonal antibody (mAb) platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The solicitation focuses on advancing the development of mAb

BARDA Announces Solicitation to Improve Monoclonal Antibody Platforms for Pre-Exposure Prophylaxis Read More »

nucleic acid-based therapeutics

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis

PrEP_Solicitation_Nucleic_Acid_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of long-acting nucleic acid-based platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The specific goals of these PrEP DEV awards include

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis Read More »

mRNA infectious diseases vaccine development

BARDA Issues RPP for Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability

24-08-mRNALongTerm_Final The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) aimed at vaccine development and response for emerging infectious diseases and rapid pandemic influenza. The RPP, numbered RRPV-24-08-mRNALongTerm, focuses on creating a lasting partnership that builds and maintains a robust mRNA preparedness and response system for pandemic influenza

BARDA Issues RPP for Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability Read More »

biologics

BARDA Issues RPP for On-Demand Manufacturing

RPP-24-02-ODM The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at the preparation for and response to public health emergencies through On-Demand Manufacturing. The RPP, numbered 24-02-ODM, focuses advancing manufacturing technologies that will improve access and enable faster, cheaper, more rapid, and flexible production of vaccines

BARDA Issues RPP for On-Demand Manufacturing Read More »

A closeup shot of a scientist conducting the gel electrophoresis biological process as part of coronavirus research

BARDA Announces Request for Project Proposals for Small Molecule Drugs

BARDA RRPV 24-03-SmMol The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) under the Rapid Response Partnership Vehicle (RRPV) for developing small molecule therapeutics aimed at COVID-19 Pre-exposure Prophylaxis (PrEP). This initiative enhances national health security by advancing medical countermeasures against SARS-CoV-2 and future health threats. BARDA’s call

BARDA Announces Request for Project Proposals for Small Molecule Drugs Read More »

BioMaP-RPP-N95-respirators

BARDA Issues RPP for N95 Respirator Production

BioMaP_RPP_24-05-N95 The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at sustaining the manufacturing capacity of N95 respirators, a crucial element in the biopharmaceutical and healthcare sectors, especially highlighted during the COVID-19 pandemic. The RPP, numbered 24-05-N95, focuses on maintaining a “warm-base” status of manufacturing capabilities

BARDA Issues RPP for N95 Respirator Production Read More »

Scroll to Top